Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ertapenem Clear all
Completed Early Phase 1 Interventional

Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis

NCT02447224
View directory record Official record
Conditions
Acute Uncomplicated Appendicitis
Interventions
1 gm IV ertapenem at enrollment, 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days, Appendectomy
Drug · Procedure
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

NCT02159859
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Ertapenem
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 88 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

NCT03357614
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Sulopenem, Sulopenem-Etzadroxil/Probenecid, Ertapenem, Ciprofloxacin, Amoxicillin-clavulanate
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Bellflower, California • Chula Vista, California • La Mesa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT03788967
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBPM-PI-HBr, Ertapenem, Dummy Infusion, Dummy tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
La Mesa, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 4 Interventional

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

NCT07376889
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

NCT04502095
View directory record Official record
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

NCT00877370
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
ertapenem
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

NCT03582007
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, One anti-pseudomonal antibiotic
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

NCT05645757
View directory record Official record
Conditions
Bacterial Infection
Interventions
Ertapenem, Placebo, WCK 6777, Zidebactam
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

NCT01265784
View directory record Official record
Conditions
Complicated Intra-abdominal Infection
Interventions
TP-434, Ertapenem, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Long Beach, California • Denver, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 1 Interventional

Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

NCT01587495
View directory record Official record
Conditions
Endometritis
Interventions
Ertapenem
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

NCT00366249
View directory record Official record
Conditions
Bacterial Infections, Diabetic Foot, Osteomyelitis
Interventions
Tigecycline, Ertapenem
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Los Angeles, California • Northridge, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

NCT03032510
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Eravacycline, Ertapenem, Placebo, Levofloxacin
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Fullerton, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

NCT01069900
View directory record Official record
Conditions
Intraabdominal Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 17 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Diego, California • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Not applicable Interventional Results available

Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

NCT04748120
View directory record Official record
Conditions
Covid19, Appendicitis, Cholecystitis, Acute, Cholecystitis; Gallstone, Cholecystitis
Interventions
Operative management, Non-operative management
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

NCT01844856
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
Eravacycline, Ertapenem, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Florence, Alabama • Mobile, Alabama • Glendale, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Withdrawn No phase listed Observational

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

NCT05255575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ertapenem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

NCT00939952
View directory record Official record
Conditions
Continuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
Interventions
ertapenem
Drug
Lead sponsor
Albany College of Pharmacy and Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Clifton Park, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion

NCT01148771
View directory record Official record
Conditions
Healthy
Interventions
ertapenem
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Sep 1, 2026, 2:52 PM EDT
Not yet recruiting Phase 2 Interventional

Cefotetan Therapy for Escherichia Coli Infections

NCT07318584
View directory record Official record
Conditions
E Coli Infection, ESBL Producing E.Coli
Interventions
Cefotetan, Carbapenems, Beta Lactam Antibiotics
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Not yet recruiting Phase 4 Interventional

PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network

NCT06920147
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Ertapenem, Cefazolin and Metronidazole.
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Not applicable Interventional Results available

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

NCT02800785
View directory record Official record
Conditions
Appendicitis
Interventions
Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
25
States / cities
Sylmar, California • Torrance, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 1, 2026, 2:52 PM EDT